Spanish Society of Radiation Oncology clinical guidelines for stereotactic body radiation therapy in lymph node oligometastases

• Published in: Clinical & translational oncology Vol. 18; no. 4; pp. 342 - 351
• Main Authors: Conde-Moreno, A. J., Lopez-Guerra, J. L., Macias, V. A., Vázquez de la Torre, M. L., Samper Ots, P., San José-Maderuelo, S., Pastor Peidro, J., López-Torrecilla, J., Expósito-Hernández, J.
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 01.04.2016
• Subjects: Clinical Guides in Oncology; Clinical Trials as Topic - standards; Humans; Lymphatic Metastasis; Medicine; Medicine & Public Health; Neoplasms - pathology; Neoplasms - surgery; Oncology; Practice Guidelines as Topic - standards; Prognosis; Radiation Oncology - standards; Radiosurgery - standards; Societies, Medical; Survival Rate; SABR; SBRT; Adenopathies; Radiosurgery; Lymph node oligometastases
• ISSN: 1699-048X; 1699-3055
• DOI: 10.1007/s12094-015-1383-y

Data in the literature support the existence of a state of limited metastases or oligometastases. Favorable outcomes have been observed in selected patients with such oligometastases that are treated with local ablative therapies, which include surgical extirpation, stereotactic body radiation therapy (SBRT), and radiofrequency ablation. The role of SBRT in the setting of lymph node oligometastases is still emerging but the early results for local control are promising. However, the biggest challenge is to identify patients who will benefit from treatment of their oligometastatic disease with local aggressive therapy. Patients are initially categorized based upon examination of the initial biopsy, location, stage, and previous treatments received. Appropriate patient management with SBRT requires an understanding of several clinicopathological features that help to identify several subsets of patients with more responsive tumors and a good tolerance to SBRT. In an effort to incorporate the most recent evidence, here the Spanish Society of Radiation Oncology presents guidelines for using SBRT in lymph node oligometastases.